Fulgent Genetics Inc (FLGT)
Return on equity (ROE)
Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net income (ttm) | US$ in thousands | -42,708 | -164,969 | -163,428 | -165,947 | -168,334 | -64,261 | -49,811 | -27,045 | 142,783 | 271,198 | 392,377 | 460,652 | 507,364 | 569,332 | 493,448 | 416,957 | 214,310 | 47,707 | 2,531 | -459 |
Total stockholders’ equity | US$ in thousands | 1,133,230 | 1,138,440 | 1,132,550 | 1,129,940 | 1,136,100 | 1,258,700 | 1,259,760 | 1,268,920 | 1,269,880 | 1,281,400 | 1,304,760 | 1,312,960 | 1,165,880 | 1,036,780 | 920,725 | 801,566 | 569,387 | 186,955 | 87,043 | 81,372 |
ROE | -3.77% | -14.49% | -14.43% | -14.69% | -14.82% | -5.11% | -3.95% | -2.13% | 11.24% | 21.16% | 30.07% | 35.08% | 43.52% | 54.91% | 53.59% | 52.02% | 37.64% | 25.52% | 2.91% | -0.56% |
December 31, 2024 calculation
ROE = Net income (ttm) ÷ Total stockholders’ equity
= $-42,708K ÷ $1,133,230K
= -3.77%
Fulgent Genetics Inc's return on equity (ROE) varied significantly over the period from March 31, 2020, to December 31, 2024. The ROE started at a negative value of -0.56% in March 2020, indicating that the company had a net loss relative to shareholders' equity.
The ROE improved steadily over the next few quarters, reaching positive territory in June 2020 at 2.91%. Subsequently, the ROE showed a remarkable increase, more than doubling by September 2020 to reach 25.52%. The trend continued to improve through December 2020 and March 2021, where ROE exceeded 50%, peaking at 54.91% in September 2021.
However, from December 2021 onwards, the ROE started to decline, dropping to 11.24% by December 2022 and turning negative in the following quarters. The ROE remained negative from March 2023 to December 2024, with the lowest value recorded at -14.82% in December 2023. There was a slight improvement in the ROE by December 2024, with the value standing at -3.77%.
Overall, Fulgent Genetics Inc's ROE exhibited a volatile pattern, experiencing significant fluctuations over the analyzed period. The company initially showed strong profitability and efficiency in utilizing shareholder equity, but the performance deteriorated in later periods, indicating challenges in generating returns for shareholders during those periods.
Peer comparison
Dec 31, 2024